Altamira Therapeutics has announced an extension of its 2022 license and distribution agreement that gave Nuance Pharma the rights to market Altamira’s Bentrio nasal spray in China, Hong Kong, Macau and South Korea. According to Altamira, Nuance has recently submitted a marketing application for Bentrio in China. The revised deal adds Singapore, Malaysia, Thailand, the Philippines, Indonesia, Vietnam, and Taiwan.
Recently Altamira announced the expansion of another distribution agreement: a 2023 deal that gave Pharma Nordic the rights to distribute Bentrio in Norway. In August 2024, the company said that Pharma Nordic had also acquired distribution rights for the nasal spray in Sweden and Denmark.
Altamira Medica Chairman and CEO Thomas Meyer commented, “We are very satisfied with the collaboration with our partner Nuance, who has shown great dedication and launched Bentrio successfully in Hong Kong. Together with Nuance, we look forward to making Bentrio available in further countries, first in the existing license territory and subsequently also in the newly added countries to provide relief to the growing number of allergic rhinitis patients in East and Southeast Asia.“
Nuance Pharma CEO Mark G. Lotter said, “We are excited to reinforce and expand our successful collaboration with Altamira on Bentrio. Bentrio offers some unique features such as immediate onset and long duration of protection against airborne particles, strong efficacy and good tolerability thanks to its drug-free and preservative-free formulation. They resonate well with medical professionals and consumers, and we look forward to rolling out the product in additional countries and marketing it through our large sales force and growing network of partners.”
Read the Altamira Therapeutics press release.
